---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-233500"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:07:48.858151+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics CFO Kristian Humer resigns; Seth Harmon appointed principal financial officer

## Summary
- Kristian Humer, CFO and CBO, resigns effective Sept 12, 2023; eligible for severance under existing agreement.
- Seth Harmon, SVP of Finance (joined May 2023), assumes role of principal financial and accounting officer.
- Harmon's base salary increased to $410,000; entitled to 12-month severance upon involuntary termination.
- Harmon previously CFO of BioNTech US subsidiary and held finance roles at Neon Therapeutics and Merrimack.
- Harmon is a CPA with prior experience at Ernst & Young.

## SEC filing metadata
- accession: 0001193125-23-233500
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/d638217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-233500
- JSON: https://secwatch.observer/filing/0001193125-23-233500.json
- Plain text: https://secwatch.observer/filing/0001193125-23-233500.txt

## Key facts
- Executive change
  Kristian Humer resigned as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc.\DE.
  - Action: resigned
  - Role: Chief Financial Officer and Chief Business Officer
  source text: On September 8, 2023, Kristian Humer, the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics, Inc. (the “Company”), resigned, effective September 12, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm
- Executive change
  Seth Harmon changed role as principal financial and accounting officer at Viridian Therapeutics, Inc.\DE.
  - Action: assumed the role
  - Role: principal financial and accounting officer
  source text: on September 12, 2023, Seth Harmon, the Company’s Senior Vice President of Finance, assumed the role of the Company’s principal financial and accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.